首页> 外文OA文献 >Integrated analysis of mRNA and miRNA profiles revealed the role of miR-193 and miR-210 as potential regulatory biomarkers in different molecular subtypes of breast cancer
【2h】

Integrated analysis of mRNA and miRNA profiles revealed the role of miR-193 and miR-210 as potential regulatory biomarkers in different molecular subtypes of breast cancer

机译:mRNA和miRNA型材的综合分析揭示了MIR-193和MIR-210作为乳腺癌不同分子亚型的潜在调节生物标志物的作用

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

Abstract Background Breast cancer is the most frequently diagnosed malignancy among women. However, the role of microRNA (miRNA) expression in breast cancer progression is not fully understood. In this study we examined predictive interactions between differentially expressed miRNAs and mRNAs in breast cancer cell lines representative of the common molecular subtypes. Integrative bioinformatics analysis identified miR-193 and miR-210 as potential regulatory biomarkers of mRNA in breast cancer. Several recent studies have investigated these miRNAs in a broad range of tumors, but the mechanism of their involvement in cancer progression has not previously been investigated. Methods The miRNA-mRNA interactions in breast cancer cell lines were identified by parallel expression analysis and miRNA target prediction programs. The expression profiles of mRNA and miRNAs from luminal (MCF-7, MCF-7/AZ and T47D), HER2 (BT20 and SK-BR3) and triple negative subtypes (Hs578T e MDA-MB-231) could be clearly separated by unsupervised analysis using HB4A cell line as a control. Breast cancer miRNA data from TCGA patients were grouped according to molecular subtypes and then used to validate these findings. Expression of miR-193 and miR-210 was investigated by miRNA transient silencing assays using the MCF7, BT20 and MDA-MB-231 cell lines. Functional studies included, xCELLigence system, ApoTox-Glo triplex assay, flow cytometry and transwell inserts were performed to determine cell proliferation, cytotoxicity, apoptosis, migration and invasion, respectively. Results The most evident effects were associated with cell proliferation after miR-210 silencing in triple negative subtype cell line MDA-MB-231. Using in silico prediction algorithms, TNFRSF10 was identified as one of the potential regulated downstream targets for both miRNAs. The TNFRSF10C and TNFRSF10D mRNA expression inversely correlated with the expression levels of miR-193 and miR210 in breast cell lines and breast cancer patients, respectively. Other potential regulated genes whose expression also inversely correlated with both miRNAs were CCND1, a known mediator on invasion and metastasis, and the tumor suppressor gene RUNX3. Conclusions In summary, our findings identify miR-193 and miR-210 as potential regulatory miRNA in different molecular subtypes of breast cancer and suggest that miR-210 may have a specific role in MDA-MB-231 proliferation. Our results highlight important new downstream regulated targets that may serve as promising therapeutic pathways for aggressive breast cancers
机译:摘要背景乳腺癌是女性最常见的恶性肿瘤。然而,MicroRNA(miRNA)表达在乳腺癌进展中的作用尚不完全理解。在该研究中,我们在代表普通分子亚型的乳腺癌细胞系中检查差异表达的miRNA和MRNA之间的预测相互作用。一体化生物信息学分析将MIR-193和MIR-210确定为乳腺癌mRNA的潜在调节生物标志物。最近的几项研究已经在广泛的肿瘤中研究了这些miRNA,但之前尚未调查其参与癌症进展的机制。方法通过并行表达分析和miRNA靶预测计划鉴定乳腺癌细胞系中的miRNA-mRNA相互作用。 MRNA和MIRNA从腔(MCF-7,MCF-7 / AZ和T47D),HER2(BT20和SK-BR3)和三负亚型(HS578T E MDA-MB-231)中的mRNA和miRNA的表达谱可以明确分离使用HB4A细胞系作为对照的分析。来自TCGA患者的乳腺癌miRNA数据根据分子亚型进行分组,然后用来验证这些发现。 MiRNA瞬时沉默测定使用MCF7,BT20和MDA-MB-231细胞对MiR-193和MiR-210的表达进行研究。包括功能性研究,Xcelligence系统,Apotox-glo三重试验,流式细胞术和Transwell插入物分别进行细胞增殖,细胞毒性,凋亡,迁移和侵袭。结果MIR-210在三阴性亚型细胞系MDA-MB-231中沉默后,最明显的效果与细胞增殖相关。在Silico预测算法中使用TNFRSF10被识别为MIRNA的潜在调节的下游靶之一。 TNFRSF10C和TNFRSF10D mRNA表达分别与乳腺细胞系和乳腺癌患者中miR-193和miR210的表达水平相反。其他潜在的调节基因,其表达也与miRNA两种逆转,是侵袭和转移的已知介质,以及肿瘤抑制基因RUNX3。总之,我们的研究结果将miR-193和miR-210鉴定为乳腺癌不同分子亚型的潜在调节miRNA,并表明miR-210可能在MDA-MB-231增殖中具有特定作用。我们的结果突出了重要的新下游受管制的目标,可作为激进乳腺癌的有前途的治疗途径

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号